Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASOX vs GX as Adjuvant Therapy for Resected Pancreatic Cancer
NCT06571461Phase 3Not yet recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Jan 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of nanoliposomal irinotecan in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Disease-free survival at 3 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06571461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571461.